Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.

• Crossref
• PubMed
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.10.3322/caac.2155130620402)| false
• Search Google Scholar
• Export Citation

National Cancer Institute. SEER cancer statistics review, 1975-2015: overview, median age at diagnosis. 2018. Available at: https://seer.cancer.gov/csr/1975_2015/. Accessed March 1, 2019.

Juliusson G. Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry. Clin Lymphoma Myeloma Leuk 2011;11(Suppl 1):S54–S59.

• Crossref
Juliusson G. Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry. Clin Lymphoma Myeloma Leuk 2011;11(Suppl 1):S54–S59.10.1016/j.clml.2011.02.003)| false
• Search Google Scholar
• Export Citation

Leone G, Pagano L, Ben-Yehuda D, et al.. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007;92:1389–1398.

• Crossref
• PubMed
Leone G, Pagano L, Ben-Yehuda D, . Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007;92:1389–1398.1776811310.3324/haematol.11034)| false
• Search Google Scholar
• Export Citation

Pagana L, Pulsoni A, Tosti ME, et al..Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia. Br J Haematol 2001;112:109–117.

• Crossref
• PubMed
Pagana L, Pulsoni A, Tosti ME, .Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia. Br J Haematol 2001;112:109–117.1122560310.1046/j.1365-2141.2001.02527.x)| false
• Search Google Scholar
• Export Citation

Pulsoni A, Pagano L, Lo Coco F, et al.. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood 2002;100:1972–1976.

• Crossref
• PubMed
Pulsoni A, Pagano L, Lo Coco F, . Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood 2002;100:1972–1976.1220035410.1182/blood-2001-12-0312)| false
• Search Google Scholar
• Export Citation

Kayser S, Döhner K, Krauter J, et al..German-Austrian AMLSG. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011;117:2137–2145.

• Crossref
• PubMed
Kayser S, Döhner K, Krauter J, .German-Austrian AMLSG. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011;117:2137–2145.2112717410.1182/blood-2010-08-301713)| false
• Search Google Scholar
• Export Citation

Larson RA. Etiology and management of therapy-related myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2007;2007:453–459.

• Crossref
Larson RA. Etiology and management of therapy-related myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2007;2007:453–459.10.1182/asheducation-2007.1.453)| false
• Search Google Scholar
• Export Citation

Hosing C, Munsell M, Yazji S, et al.. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. Ann Oncol 2002;13:450–459.

• Crossref
• PubMed
Hosing C, Munsell M, Yazji S, . Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. Ann Oncol 2002;13:450–459.1199647810.1093/annonc/mdf109)| false
• Search Google Scholar
• Export Citation

Lenz G, Dreyling M, Schiegnitz E, et al.. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004;22:4926–4933.

Lenz G, Dreyling M, Schiegnitz E, . Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004;22:4926–4933.)| false
• Search Google Scholar
• Export Citation

Ferrara F, Mirto S. Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly. Br J Haematol 1996;92:627–631.

• Crossref
• PubMed
Ferrara F, Mirto S. Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly. Br J Haematol 1996;92:627–631.10.1046/j.1365-2141.1996.00398.x8616027)| false
• Search Google Scholar
• Export Citation

Yamauchi T, Negoro E, Lee S, et al.. A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res 2013;33:3947–3951.

• PubMed
Yamauchi T, Negoro E, Lee S, . A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res 2013;33:3947–3951.24023333)| false
• Search Google Scholar
• Export Citation

Ley TJ, Miller C, Ding L, et al..Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368:2059–2074.

• Crossref
• PubMed
Ley TJ, Miller C, Ding L, .Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368:2059–2074.10.1056/NEJMoa130168923634996)| false
• Search Google Scholar
• Export Citation

Döhner H, Estey E, Grimwade D, et al.. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424–447.

• Crossref
Döhner H, Estey E, Grimwade D, . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424–447.10.1182/blood-2016-08-733196)| false
• Search Google Scholar
• Export Citation

Papaemmanuil E, Gerstung M, Bullinger L, et al.. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016;374:2209–2221.

• Crossref
• PubMed
Papaemmanuil E, Gerstung M, Bullinger L, . Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016;374:2209–2221.2727656110.1056/NEJMoa1516192)| false
• Search Google Scholar
• Export Citation

Schuurhuis GJ, Heuser M, Freeman S, et al.. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018;131:1275–1291.

• Crossref
• PubMed
Schuurhuis GJ, Heuser M, Freeman S, . Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018;131:1275–1291.2933022110.1182/blood-2017-09-801498)| false
• Search Google Scholar
• Export Citation

Fernandez HF, Sun Z, Yao X, et al.. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249–1259.

• Crossref
• PubMed
Fernandez HF, Sun Z, Yao X, . Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249–1259.10.1056/NEJMoa090454419776406)| false
• Search Google Scholar
• Export Citation

Luskin MR, Lee JW, Fernandez HF, et al.. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood 2016;127:1551–1558.

• Crossref
• PubMed
Luskin MR, Lee JW, Fernandez HF, . Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood 2016;127:1551–1558.10.1182/blood-2015-07-65740326755712)| false
• Search Google Scholar
• Export Citation

Pautas C, Merabet F, Thomas X, et al.. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010;28:808–814.

• Crossref
• PubMed
Pautas C, Merabet F, Thomas X, . Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010;28:808–814.10.1200/JCO.2009.23.265220048183)| false
• Search Google Scholar
• Export Citation

Teuffel O, Leibundgut K, Lehrnbecher T, et al.. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol 2013;161:192–203.

• Crossref
• PubMed
Teuffel O, Leibundgut K, Lehrnbecher T, . Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol 2013;161:192–203.10.1111/bjh.1223323398482)| false
• Search Google Scholar
• Export Citation

Burnett AK, Russell NH, Hills RK, et al..UK NCRI AML Study Group. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 2015;125:3878–3885.

• Crossref
• PubMed
Burnett AK, Russell NH, Hills RK, .UK NCRI AML Study Group. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 2015;125:3878–3885.10.1182/blood-2015-01-62344725833957)| false
• Search Google Scholar
• Export Citation

Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015;373:1136–1152.

• Crossref
• PubMed
Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015;373:1136–1152.10.1056/NEJMra140618426376137)| false
• Search Google Scholar
• Export Citation

Sievers EL, Larson RA, Stadtmauer EA, et al..Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001;19:3244–3254.

• Crossref
• PubMed
Sievers EL, Larson RA, Stadtmauer EA, .Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001;19:3244–3254.1143289210.1200/JCO.2001.19.13.3244)| false
• Search Google Scholar
• Export Citation

Petersdorf S, Kopecky K, Stuart RK, et al.. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 2009;114:326– 327.

Petersdorf S, Kopecky K, Stuart RK, . Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 2009;114:326–327.)| false
• Search Google Scholar
• Export Citation

Petersdorf SH, Kopecky KJ, Slovak M, et al.. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013;121:4854–4860.

• Crossref
• PubMed
Petersdorf SH, Kopecky KJ, Slovak M, . A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013;121:4854–4860.10.1182/blood-2013-01-46670623591789)| false
• Search Google Scholar
• Export Citation

Burnett AK, Hills RK, Milligan D, et al.. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011;29:369–377.

• Crossref
• PubMed
Burnett AK, Hills RK, Milligan D, . Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011;29:369–377.2117289110.1200/JCO.2010.31.4310)| false
• Search Google Scholar
• Export Citation

Hills RK, Castaigne S, Appelbaum FR, et al.. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014;15:986–996.

• Crossref
• PubMed
Hills RK, Castaigne S, Appelbaum FR, . Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014;15:986–996.2500825810.1016/S1470-2045(14)70281-5)| false
• Search Google Scholar
• Export Citation

Boissel N, Renneville A, Leguay T, et al.. Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. Haematologica 2015;100:780–785.

• Crossref
• PubMed
Boissel N, Renneville A, Leguay T, . Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. Haematologica 2015;100:780–785.10.3324/haematol.2014.11488425715404)| false
• Search Google Scholar
• Export Citation

Paschka P, Schlenk RF, Weber D, et al.. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. Leukemia 2018;32:1621–1630.

• Crossref
• PubMed
Paschka P, Schlenk RF, Weber D, . Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. Leukemia 2018;32:1621–1630.10.1038/s41375-018-0129-629720733)| false
• Search Google Scholar
• Export Citation

Fischer T, Stone RM, Deangelo DJ, et al.. Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010;28:4339–4345.

• Crossref
• PubMed
Fischer T, Stone RM, Deangelo DJ, . Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010;28:4339–4345.10.1200/JCO.2010.28.967820733134)| false
• Search Google Scholar
• Export Citation

Stone RM, Fischer T, Paquette R, et al.. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 2012;26:2061–2068.

• Crossref
• PubMed
Stone RM, Fischer T, Paquette R, . Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 2012;26:2061–2068.10.1038/leu.2012.11522627678)| false
• Search Google Scholar
• Export Citation

Stone RM, Mandrekar SJ, Sanford BL, et al.. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017;377:454–464.

• Crossref
• PubMed
Stone RM, Mandrekar SJ, Sanford BL, . Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017;377:454–464.2864411410.1056/NEJMoa1614359)| false
• Search Google Scholar
• Export Citation

Burnett AK, Russell NH, Hills RK. United Kingdom National Cancer Research Institute Acute Myeloid Leukemia Study Group. Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. Blood 2016;128:449–452.

• Crossref
• PubMed
Burnett AK, Russell NH, Hills RK. United Kingdom National Cancer Research Institute Acute Myeloid Leukemia Study Group. Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. Blood 2016;128:449–452.2726808510.1182/blood-2016-04-712091)| false
• Search Google Scholar
• Export Citation

Lee JH, Joo YD, Kim H, et al..Cooperative Study Group A for Hematology. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 2011;118:3832–3841.

• Crossref
• PubMed
Lee JH, Joo YD, Kim H, .Cooperative Study Group A for Hematology. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 2011;118:3832–3841.10.1182/blood-2011-06-36141021828126)| false
• Search Google Scholar
• Export Citation

Lee JH, Kim H, Joo YD, et al..Cooperative Study Group A for Hematology. Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia. J Clin Oncol 2017;35:2754–2763.

• Crossref
• PubMed
Lee JH, Kim H, Joo YD, .Cooperative Study Group A for Hematology. Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia. J Clin Oncol 2017;35:2754–2763.10.1200/JCO.2017.72.861828632487)| false
• Search Google Scholar
• Export Citation

Granfeldt Østgård LS, Medeiros BC, Sengeløv H, et al.. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol 2015;33:3641–3649.

• Crossref
Granfeldt Østgård LS, Medeiros BC, Sengeløv H, . Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol 2015;33:3641–3649.10.1200/JCO.2014.60.0890)| false
• Search Google Scholar
• Export Citation

Grimwade D, Hills RK, Moorman AV, et al..National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354–365.

• Crossref
• PubMed
Grimwade D, Hills RK, Moorman AV, .National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354–365.2038579310.1182/blood-2009-11-254441)| false
• Search Google Scholar
• Export Citation

Cortes JE, Goldberg SL, Feldman EJ, et al.. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer 2015;121:234–242.

• Crossref
• PubMed
Cortes JE, Goldberg SL, Feldman EJ, . Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer 2015;121:234–242.10.1002/cncr.2897425223583)| false
• Search Google Scholar
• Export Citation

Lancet JE, Cortes JE, Hogge DE, et al.. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood 2014;123:3239–3246.

• Crossref
• PubMed
Lancet JE, Cortes JE, Hogge DE, . Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood 2014;123:3239–3246.10.1182/blood-2013-12-54097124687088)| false
• Search Google Scholar
• Export Citation

Lancet JE, Uy GL, Cortes JE, et al.. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018;36:2684–2692.

• Crossref
• PubMed
Lancet JE, Uy GL, Cortes JE, . CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018;36:2684–2692.10.1200/JCO.2017.77.611230024784)| false
• Search Google Scholar
• Export Citation

Holowiecki J, Grosicki S, Giebel S, et al.. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol 2012;30:2441–2448.

• Crossref
• PubMed
Holowiecki J, Grosicki S, Giebel S, . Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol 2012;30:2441–2448.10.1200/JCO.2011.37.128622508825)| false
• Search Google Scholar
• Export Citation

Willemze R, Suciu S, Meloni G, et al.. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol 2014;32:219–228.

• Crossref
• PubMed
Willemze R, Suciu S, Meloni G, . High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol 2014;32:219–228.2429794010.1200/JCO.2013.51.8571)| false
• Search Google Scholar
• Export Citation

Bishop JF, Matthews JP, Young GA, et al.. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710–1717.

• PubMed
Bishop JF, Matthews JP, Young GA, . A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710–1717.8634416)| false
• Search Google Scholar
• Export Citation

Bishop JF, Matthews JP, Young GA, et al.. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leuk Lymphoma 1998;28:315–327.

• Crossref
Bishop JF, Matthews JP, Young GA, . Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leuk Lymphoma 1998;28:315–327.10.3109/10428199809092687)| false
• Search Google Scholar
• Export Citation

Weick JK, Kopecky KJ, Appelbaum FR, et al.. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;88:2841–2851.

Weick JK, Kopecky KJ, Appelbaum FR, . A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;88:2841–2851.)| false
• Search Google Scholar
• Export Citation

Mayer RJ, Davis RB, Schiffer CA, et al..Cancer and Leukemia Group B. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994;331:896–903.

• Crossref
• PubMed
Mayer RJ, Davis RB, Schiffer CA, .Cancer and Leukemia Group B. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994;331:896–903.10.1056/NEJM1994100633114028078551)| false
• Search Google Scholar
• Export Citation

Li W, Gong X, Sun M, et al.. High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis. PLoS One 2014;9:e110153.

• Crossref
• PubMed
Li W, Gong X, Sun M, . High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis. PLoS One 2014;9:e110153.2529962310.1371/journal.pone.0110153)| false
• Search Google Scholar
• Export Citation

Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer 2006;107:116–124.

• Crossref
• PubMed
Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer 2006;107:116–124.10.1002/cncr.2154316721819)| false
• Search Google Scholar
• Export Citation

Bloomfield CD, Lawrence D, Byrd JC, et al.. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173–4179.

• PubMed
Bloomfield CD, Lawrence D, Byrd JC, . Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173–4179.9751631)| false
• Search Google Scholar
• Export Citation

Burnett AK, Russell NH, Hills RK, et al.. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 2013;31:3360–3368.

• Crossref
• PubMed
Burnett AK, Russell NH, Hills RK, . Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 2013;31:3360–3368.10.1200/JCO.2012.47.487423940227)| false
• Search Google Scholar
• Export Citation

Löwenberg B, Pabst T, Maertens J, et al..Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood 2017;129:1636–1645.

• Crossref
• PubMed
Löwenberg B, Pabst T, Maertens J, .Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood 2017;129:1636–1645.10.1182/blood-2016-10-74061328049642)| false
• Search Google Scholar
• Export Citation

Al-Ali HK, Brand R, van Biezen A, et al.. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 2007;21:1945–1951.

Al-Ali HK, Brand R, van Biezen A, . A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 2007;21:1945–1951.)| false
• Search Google Scholar
• Export Citation

Smith M, Barnett M, Bassan R, et al.. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 2004;50:197–222.

• Crossref
• PubMed
Smith M, Barnett M, Bassan R, . Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 2004;50:197–222.10.1016/j.critrevonc.2003.11.00215182826)| false
• Search Google Scholar
• Export Citation

Cairoli R, Beghini A, Grillo G, et al.. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006;107:3463–3468.

• Crossref
• PubMed
Cairoli R, Beghini A, Grillo G, . Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006;107:3463–3468.1638492510.1182/blood-2005-09-3640)| false
• Search Google Scholar
• Export Citation

Paschka P, Marcucci G, Ruppert AS, et al..Cancer and Leukemia Group B. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006;24:3904–3911.

• Crossref
Paschka P, Marcucci G, Ruppert AS, .Cancer and Leukemia Group B. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006;24:3904–3911.10.1200/JCO.2006.06.9500)| false
• Search Google Scholar
• Export Citation

Park SH, Chi HS, Min SK, et al.. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res 2011;35:1376–1383.

• Crossref
• PubMed
Park SH, Chi HS, Min SK, . Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res 2011;35:1376–1383.10.1016/j.leukres.2011.06.00321715005)| false
• Search Google Scholar
• Export Citation

Chen W, Xie H, Wang H, et al.. Prognostic significance of KIT mutations in core-binding factor acute myeloid leukemia: a systematic review and meta-analysis. PLoS One 2016;11:e0146614.

• Crossref
• PubMed
Chen W, Xie H, Wang H, . Prognostic significance of KIT mutations in core-binding factor acute myeloid leukemia: a systematic review and meta-analysis. PLoS One 2016;11:e0146614.2677137610.1371/journal.pone.0146614)| false
• Search Google Scholar
• Export Citation

Jaramillo S, Benner A, Krauter J, et al.. Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. Blood Cancer J 2017;7:e564.

• Crossref
• PubMed
Jaramillo S, Benner A, Krauter J, . Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. Blood Cancer J 2017;7:e564.10.1038/bcj.2017.4528548643)| false
• Search Google Scholar
• Export Citation

Löwenberg B, Pabst T, Vellenga E, et al..Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011;364:1027–1036.

• Crossref
• PubMed
Löwenberg B, Pabst T, Vellenga E, .Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011;364:1027–1036.10.1056/NEJMoa101022221410371)| false
• Search Google Scholar
• Export Citation

Suciu S, Mandelli F, de Witte T, et al..EORTC and GIMEMA Leukemia Groups. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003;102:1232–1240.

• Crossref
• PubMed
Suciu S, Mandelli F, de Witte T, .EORTC and GIMEMA Leukemia Groups. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003;102:1232–1240.10.1182/blood-2002-12-371412714526)| false
• Search Google Scholar
• Export Citation

Slovak ML, Kopecky KJ, Cassileth PA, et al.. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075–4083.

Slovak ML, Kopecky KJ, Cassileth PA, . Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075–4083.)| false
• Search Google Scholar
• Export Citation

Burnett AK, Wheatley K, Goldstone AH, et al..Medical Research Council Adult and Paediatric Working Parties. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002;118:385–400.

• Crossref
• PubMed
Burnett AK, Wheatley K, Goldstone AH, .Medical Research Council Adult and Paediatric Working Parties. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002;118:385–400.10.1046/j.1365-2141.2002.03724.x12139722)| false
• Search Google Scholar
• Export Citation

Döhner K, Schlenk RF, Habdank M, et al.. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005;106:3740–3746.

• Crossref
• PubMed
Döhner K, Schlenk RF, Habdank M, . Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005;106:3740–3746.10.1182/blood-2005-05-216416051734)| false
• Search Google Scholar
• Export Citation

Schnittger S, Kohl TM, Haferlach T, et al.. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006;107:1791–1799.

• Crossref
• PubMed
Schnittger S, Kohl TM, Haferlach T, . KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006;107:1791–1799.10.1182/blood-2005-04-146616254134)| false
• Search Google Scholar
• Export Citation

Röllig C, Bornhäuser M, Thiede C, et al.. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol 2011;29:2758–2765.

• Crossref
• PubMed
Röllig C, Bornhäuser M, Thiede C, . Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol 2011;29:2758–2765.10.1200/JCO.2010.32.850021632498)| false
• Search Google Scholar
• Export Citation

Aldoss I, Pullarkat V. Therapy-related acute myeloid leukemia with favorable cytogenetics: still favorable? Leuk Res 2012;36:1547–1551.

• Crossref
• PubMed
Aldoss I, Pullarkat V. Therapy-related acute myeloid leukemia with favorable cytogenetics: still favorable? Leuk Res 2012;36:1547–1551.10.1016/j.leukres.2012.09.00823031555)| false
• Search Google Scholar
• Export Citation

Farag SS, Ruppert AS, Mrózek K, et al.. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol 2005;23:482–493.

• Crossref
Farag SS, Ruppert AS, Mrózek K, . Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol 2005;23:482–493.10.1200/JCO.2005.06.090)| false
• Search Google Scholar
• Export Citation

Stone RM, Mandrekar S, Sanford BL, et al.. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myEloid leukemia (AML) patients (pts) Age 18–60 with FLT3 mutations (muts) [abstract]. Blood 2015;126:6.

Stone RM, Mandrekar S, Sanford BL, . The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myEloid leukemia (AML) patients (pts) Age 18–60 with FLT3 mutations (muts) [abstract]. Blood 2015;126:6.)| false
• Search Google Scholar
• Export Citation

Appelbaum FR, Gundacker H, Head DR, et al.. Age and acute myeloid leukemia. Blood 2006;107:3481–3485.

• Crossref
• PubMed
Appelbaum FR, Gundacker H, Head DR, . Age and acute myeloid leukemia. Blood 2006;107:3481–3485.10.1182/blood-2005-09-372416455952)| false
• Search Google Scholar
• Export Citation

Kantarjian H, O’brien S, Cortes J, et al.. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106:1090–1098.

• Crossref
• PubMed
Kantarjian H, O’brien S, Cortes J, . Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106:1090–1098.1643538610.1002/cncr.21723)| false
• Search Google Scholar
• Export Citation

Klepin HD, Geiger AM, Tooze JA, et al.. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood 2013;121:4287–4294.

• Crossref
• PubMed
Klepin HD, Geiger AM, Tooze JA, . Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood 2013;121:4287–4294.10.1182/blood-2012-12-47168023550038)| false
• Search Google Scholar
• Export Citation

Sherman AE, Motyckova G, Fega KR, et al.. Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res 2013;37:998–1003.

• Crossref
• PubMed
Sherman AE, Motyckova G, Fega KR, . Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res 2013;37:998–1003.10.1016/j.leukres.2013.05.01323747082)| false
• Search Google Scholar
• Export Citation

Krug U, Röllig C, Koschmieder A, et al..Study Alliance Leukemia Investigators. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2010;376:2000–2008.

• Crossref
• PubMed
Krug U, Röllig C, Koschmieder A, .Study Alliance Leukemia Investigators. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2010;376:2000–2008.10.1016/S0140-6736(10)62105-821131036)| false
• Search Google Scholar
• Export Citation

Walter RB, Othus M, Borthakur G, et al.. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011;29:4417–4424.

• Crossref
• PubMed
Walter RB, Othus M, Borthakur G, . Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011;29:4417–4424.10.1200/JCO.2011.35.752521969499)| false
• Search Google Scholar
• Export Citation

Sorror ML, Storer BE, Fathi AT, et al.. Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality. JAMA Oncol 2017;3:1675–1682.

• Crossref
• PubMed
Sorror ML, Storer BE, Fathi AT, . Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality. JAMA Oncol 2017;3:1675–1682.10.1001/jamaoncol.2017.271428880971)| false
• Search Google Scholar
• Export Citation

Gardin C, Turlure P, Fagot T, et al.. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007;109:5129–5135.

• Crossref
• PubMed
Gardin C, Turlure P, Fagot T, . Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007;109:5129–5135.10.1182/blood-2007-02-06966617341661)| false
• Search Google Scholar
• Export Citation

Gardin C, Chevret S, Pautas C, et al.. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. J Clin Oncol 2013;31:321–327.

• Crossref
• PubMed
Gardin C, Chevret S, Pautas C, . Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. J Clin Oncol 2013;31:321–327.10.1200/JCO.2011.40.364223248249)| false
• Search Google Scholar
• Export Citation

Löwenberg B, Ossenkoppele GJ, van Putten W, et al..Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361:1235–1248. [Correction available at https://www.nejm.org/doi/full/10.1056/NEJMx100006.]

• Crossref
• PubMed
Löwenberg B, Ossenkoppele GJ, van Putten W, .Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361:1235–1248. [Correction available at https://www.nejm.org/doi/full/10.1056/NEJMx100006.]10.1056/NEJMoa090140919776405)| false
• Search Google Scholar
• Export Citation

Burnett AK, Russell NH, Hunter AE, et al..UK National Cancer Research Institute AML Working Group. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 2013;122:1384–1394.

• Crossref
• PubMed
Burnett AK, Russell NH, Hunter AE, .UK National Cancer Research Institute AML Working Group. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 2013;122:1384–1394.2383834910.1182/blood-2013-04-496596)| false
• Search Google Scholar
• Export Citation

Faderl S, Ravandi F, Huang X, et al.. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638–1645.

• Crossref
• PubMed
Faderl S, Ravandi F, Huang X, . A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638–1645.1856585310.1182/blood-2007-11-124602)| false
• Search Google Scholar
• Export Citation

Foran JM, Sun Z, Claxton DF, et al.. Importance of achieving complete remission (CR) after intensive therapy for acute myeloid leukemia (AML) in older adults age ≥60 years: analysis of risk factors for early mortality and re-induction, and impact of quality of response on overall survival (OS) in the ECOG-ACRIN E2906 randomized trial [abstract]. Blood 2016;128:339.

Foran JM, Sun Z, Claxton DF, . Importance of achieving complete remission (CR) after intensive therapy for acute myeloid leukemia (AML) in older adults age ≥60 years: analysis of risk factors for early mortality and re-induction, and impact of quality of response on overall survival (OS) in the ECOG-ACRIN E2906 randomized trial [abstract]. Blood 2016;128:339.)| false
• Search Google Scholar
• Export Citation

Kantarjian HM, Erba HP, Claxton D, et al.. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010;28:549–555.

• Crossref
• PubMed
Kantarjian HM, Erba HP, Claxton D, . Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010;28:549–555.2002680510.1200/JCO.2009.23.3130)| false
• Search Google Scholar
• Export Citation

Martínez-Cuadrón D, Montesinos P, Oriol A, et al.. Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia. Ann Hematol 2014;93:43–46.

• Crossref
• PubMed
Martínez-Cuadrón D, Montesinos P, Oriol A, . Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia. Ann Hematol 2014;93:43–46.10.1007/s00277-013-1914-y24081577)| false
• Search Google Scholar
• Export Citation

Amadori S, Suciu S, Stasi R, et al.. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). J Clin Oncol 2013;31:4424–4430.

• Crossref
• PubMed
Amadori S, Suciu S, Stasi R, . Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). J Clin Oncol 2013;31:4424–4430.10.1200/JCO.2013.49.077124127442)| false
• Search Google Scholar
• Export Citation

Burnett AK, Russell NH, Hills RK, et al.. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012;30:3924–3931.

• Crossref
• PubMed
Burnett AK, Russell NH, Hills RK, . Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012;30:3924–3931.10.1200/JCO.2012.42.296422851554)| false
• Search Google Scholar
• Export Citation

Castaigne S, Pautas C, Terré C, et al..Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012;379:1508–1516.

• Crossref
• PubMed
Castaigne S, Pautas C, Terré C, .Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012;379:1508–1516.2248294010.1016/S0140-6736(12)60485-1)| false
• Search Google Scholar
• Export Citation

Loke J, Khan JN, Wilson JS, et al.. Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Ann Hematol 2015;94:361–373.

• Crossref
• PubMed
Loke J, Khan JN, Wilson JS, . Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Ann Hematol 2015;94:361–373.2528416610.1007/s00277-014-2218-6)| false
• Search Google Scholar
• Export Citation

Kharfan-Dabaja MA, Hamadani M, Reljic T, et al.. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol 2013;163:315–325.

• Crossref
• PubMed
Kharfan-Dabaja MA, Hamadani M, Reljic T, . Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol 2013;163:315–325.2403328010.1111/bjh.12528)| false
• Search Google Scholar
• Export Citation

Li X, Xu SN, Qin DB, et al.. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials. Ann Oncol 2014;25:455–461.

• Crossref
• PubMed
Li X, Xu SN, Qin DB, . Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials. Ann Oncol 2014;25:455–461.10.1093/annonc/mdt56624478322)| false
• Search Google Scholar
• Export Citation

Schlenk RF, Weber D, Fiedler W, et al..German-Austrian AML Study Group. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood 2019;133:840–851.

• Crossref
• PubMed
Schlenk RF, Weber D, Fiedler W, .German-Austrian AML Study Group. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood 2019;133:840–851.10.1182/blood-2018-08-86945330563875)| false
• Search Google Scholar
• Export Citation

Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al..International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223–232.

• Crossref
• PubMed
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, .International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223–232.10.1016/S1470-2045(09)70003-819230772)| false
• Search Google Scholar
• Export Citation

Fenaux P, Mufti GJ, Hellström-Lindberg E, et al.. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562–569.